REGENERON PHARMACEUTICALS, INC. (REGN) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
68/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseREGN / S&P -19.18% / 15.20% |
LoseREGN / S&P 9.29% / 15.00% |
LoseREGN / S&P 1.86% / 50.40% |
| 2026-Q11/3 |
WinREGN / S&P 0.22% / -4.33% |
LoseREGN / S&P 5.92% / 11.30% |
LoseREGN / S&P 4.37% / 27.70% |
| 2025-Q41/3 |
WinREGN / S&P 37.45% / 2.65% |
LoseREGN / S&P 0.99% / 9.00% |
LoseREGN / S&P 8.45% / 13.40% |
| 2025-Q30/3 |
LoseREGN / S&P 7.26% / 8.12% |
LoseREGN / S&P 2.89% / 4.61% |
LoseREGN / S&P 3.44% / 13.45% |
| 2025-Q21/3 |
LoseREGN / S&P -17.10% / 10.94% |
WinREGN / S&P 5.38% / 4.83% |
LoseREGN / S&P 5.19% / 10.63% |
| 2025-Q12/3 |
LoseREGN / S&P -10.85% / -4.27% |
WinREGN / S&P 7.52% / 4.98% |
WinREGN / S&P 16.15% / 10.57% |
| 2024-Q42/3 |
LoseREGN / S&P -32.24% / 2.41% |
WinREGN / S&P 8.27% / 5.25% |
WinREGN / S&P 10.27% / 6.15% |
| 2024-Q31/3 |
LoseREGN / S&P 0.02% / 5.89% |
LoseREGN / S&P 5.72% / 5.89% |
WinREGN / S&P 15.32% / 6.11% |
| 2024-Q22/3 |
WinREGN / S&P 9.20% / 4.28% |
WinREGN / S&P 6.46% / 5.38% |
LoseREGN / S&P -0.13% / 5.12% |
| 2024-Q11/3 |
LoseREGN / S&P 9.59% / 10.56% |
WinREGN / S&P 5.90% / 5.71% |
LoseREGN / S&P -7.96% / 5.59% |
| 2023-Q41/3 |
LoseREGN / S&P 6.72% / 11.69% |
WinREGN / S&P 7.76% / 6.81% |
LoseREGN / S&P -9.08% / 7.78% |
| 2023-Q31/3 |
WinREGN / S&P 14.53% / -3.27% |
LoseREGN / S&P -4.47% / 7.52% |
LoseREGN / S&P -26.09% / -5.03% |
| 2023-Q20/3 |
LoseREGN / S&P -12.55% / 8.74% |
LoseREGN / S&P -10.94% / 9.50% |
LoseREGN / S&P -24.50% / -8.57% |
| 2023-Q11/3 |
WinREGN / S&P 13.89% / 7.50% |
LoseREGN / S&P -25.07% / 10.77% |
LoseREGN / S&P -47.88% / -15.69% |
| 2022-Q40/3 |
LoseREGN / S&P 4.74% / 7.56% |
LoseREGN / S&P -24.26% / 11.88% |
LoseREGN / S&P -46.95% / -17.99% |
| 2022-Q31/3 |
WinREGN / S&P 16.53% / -4.88% |
LoseREGN / S&P 1.24% / 13.47% |
LoseREGN / S&P -24.19% / -1.41% |
| 2022-Q22/3 |
WinREGN / S&P -15.36% / -16.10% |
WinREGN / S&P 14.88% / 13.71% |
LoseREGN / S&P -9.93% / 11.04% |
| 2022-Q13/3 |
WinREGN / S&P 10.59% / -4.60% |
WinREGN / S&P 79.48% / 15.97% |
WinREGN / S&P 100.26% / 42.23% |
| 2021-Q42/3 |
LoseREGN / S&P 4.35% / 11.03% |
WinREGN / S&P 89.14% / 15.00% |
WinREGN / S&P 135.60% / 96.40% |
| 2021-Q33/3 |
WinREGN / S&P 8.35% / 0.58% |
WinREGN / S&P 70.61% / 10.77% |
WinREGN / S&P 128.70% / 69.42% |
| 2021-Q23/3 |
WinREGN / S&P 18.05% / 8.55% |
WinREGN / S&P 67.64% / 6.58% |
WinREGN / S&P 115.38% / 51.81% |
| 2021-Q12/3 |
LoseREGN / S&P -2.06% / 6.17% |
WinREGN / S&P 31.15% / -1.06% |
WinREGN / S&P 77.22% / 7.39% |
| 2020-Q42/3 |
LoseREGN / S&P -13.70% / 12.15% |
WinREGN / S&P 29.58% / -3.72% |
WinREGN / S&P 65.80% / -33.42% |
| 2020-Q32/3 |
LoseREGN / S&P -10.24% / 8.93% |
WinREGN / S&P 56.97% / -2.04% |
WinREGN / S&P 46.41% / -27.10% |
| 2020-Q23/3 |
WinREGN / S&P 27.72% / 20.54% |
WinREGN / S&P 48.45% / -0.46% |
WinREGN / S&P 43.52% / -27.11% |
| 2020-Q13/3 |
WinREGN / S&P 30.04% / -19.60% |
WinREGN / S&P 40.08% / 3.47% |
WinREGN / S&P -5.87% / -14.75% |
| 2019-Q42/3 |
WinREGN / S&P 35.36% / 9.07% |
WinREGN / S&P 27.44% / 5.36% |
LoseREGN / S&P -13.38% / 2.99% |
| 2019-Q31/3 |
LoseREGN / S&P -11.37% / 1.70% |
LoseREGN / S&P -20.56% / 5.02% |
WinREGN / S&P 19.36% / 0.21% |
| 2019-Q21/3 |
LoseREGN / S&P -23.77% / 4.30% |
LoseREGN / S&P -19.77% / 6.64% |
WinREGN / S&P 30.36% / 8.65% |
| 2019-Q11/3 |
LoseREGN / S&P 9.94% / 13.65% |
LoseREGN / S&P -17.45% / 8.12% |
WinREGN / S&P 71.51% / 14.29% |
| 2018-Q42/3 |
WinREGN / S&P -7.56% / -13.52% |
LoseREGN / S&P -12.37% / 9.05% |
WinREGN / S&P 106.40% / 18.23% |
| 2018-Q33/3 |
WinREGN / S&P 17.12% / 7.71% |
WinREGN / S&P 15.39% / 10.21% |
WinREGN / S&P 42.14% / 19.06% |
| 2018-Q22/3 |
LoseREGN / S&P 0.18% / 3.43% |
WinREGN / S&P 18.46% / 9.03% |
WinREGN / S&P 38.55% / 14.46% |
| 2018-Q12/3 |
LoseREGN / S&P -8.41% / -0.76% |
WinREGN / S&P 21.82% / 7.68% |
WinREGN / S&P 48.26% / 12.46% |
| 2017-Q42/3 |
LoseREGN / S&P -15.92% / 6.64% |
WinREGN / S&P 20.82% / 7.03% |
WinREGN / S&P 33.33% / 13.82% |
| 2017-Q32/3 |
LoseREGN / S&P -8.96% / 4.48% |
WinREGN / S&P 16.59% / 5.68% |
WinREGN / S&P 59.80% / 17.57% |
| 2017-Q23/3 |
WinREGN / S&P 26.74% / 3.09% |
WinREGN / S&P 12.63% / 4.83% |
WinREGN / S&P 54.66% / 17.74% |
| 2017-Q12/3 |
LoseREGN / S&P 5.56% / 6.07% |
WinREGN / S&P 12.26% / 3.67% |
WinREGN / S&P 29.04% / 13.32% |
| 2016-Q42/3 |
LoseREGN / S&P -8.69% / 3.82% |
WinREGN / S&P 18.44% / 2.09% |
WinREGN / S&P 40.47% / 7.05% |
| 2016-Q33/3 |
WinREGN / S&P 15.12% / 3.85% |
WinREGN / S&P 24.26% / 0.20% |
WinREGN / S&P 38.91% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | REGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 39.81% | 20.78% |
| Annualized return | 39.81% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | REGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 19.73% | 83.14% |
| Annualized return | 3.67% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | REGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 107.25% | 319.30% |
| Annualized return | 7.56% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |